Pfizer gets mixed results against IPP claims

The state antitrust claims brought by a class of indirect purchasers of Pfizer’s cholesterol medication are not pre-empted by federal patent law, a New Jersey federal judge has ruled – but state procedural laws impede some of the claims.

Get unlimited access to all Global Competition Review content